| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | SVTLE |
| Uniprot No | F8S114 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-262aa |
| 氨基酸序列 | VIGGDECNINEHRFLVALYDYWSQSFLCGGTLINEEWVLTAKHCDRTHILIYVGVHDRSVQFDKEQRRFPKEKYFFDCSNNFTKWDKDIMLIRLNKPVSYSEHIAPLSLPSSPPIVGSVCRAMGWGQTTSPQETLPDVPHCANINLLDYEVCRTAHPQFRLPATSRTLCAGVLEGGIDTCNRDSGGPLICNGQFQGIVFWGPDPCAQPDKPGLYTKVFDHLDWIQSIIAGEKTVNCPP |
| 预测分子量 | 42.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SVTLE重组蛋白的3-4条虚构参考文献示例(假设SVTLE为蛇毒来源的重组毒素蛋白，实际文献需根据具体名称核实)：
---
1. **文献名称**: *"Efficient expression and purification of recombinant SVTLE toxin in Pichia pastoris for antivenom production"*
**作者**: Chen, L.; Wang, Y.; Li, J.
**摘要**: 本研究利用毕赤酵母表达系统高效表达SVTLE重组蛋白，通过亲和层析纯化获得高纯度产物。实验表明，该重组蛋白可特异性结合蛇毒抗体，为抗蛇毒血清开发提供了新策略。
2. **文献名称**: *"Structural and functional characterization of SVTLE phospholipase A2: Insights into its catalytic mechanism"*
**作者**: Silva, R.R.; Fernández, J.
**摘要**: 通过X射线晶体学解析了SVTLE的磷脂酶A2结构，发现其活性位点关键氨基酸残基对底物水解至关重要。体外实验证实重组SVTLE具有强效溶血活性，为毒素抑制剂设计奠定基础。
3. **文献名称**: *"Development of a SVTLE-based biosensor for heavy metal detection"*
**作者**: Gupta, S.; Patel, K.
**摘要**: 将重组SVTLE蛋白与纳米金颗粒结合，构建了一种新型生物传感器。该传感器对汞离子(Hg²⁺)表现出高灵敏度和选择性，拓展了毒素蛋白在环境监测中的应用。
4. **文献名称**: *"Immunogenicity assessment of recombinant SVTLE in murine models"*
**作者**: Tanaka, M.; Suzuki, H.
**摘要**: 在小鼠模型中评估重组SVTLE的免疫原性，发现其能诱导高水平中和抗体，显著降低蛇毒攻击后的死亡率，提示其作为疫苗候选的潜力。
---
**注**：以上文献为示例，实际研究中需根据SVTLE的具体定义(如是否涉及病毒、细菌或合成蛋白)检索真实数据库(如PubMed、Web of Science)。若需真实文献，请提供更完整的蛋白名称或研究背景。
**Background of SVTLE Recombinant Protein**
The SVTLE recombinant protein is a bioengineered antigen designed for vaccine development, particularly against viral pathogens. Leveraging recombinant DNA technology, the protein is synthesized by inserting genetic sequences encoding specific viral epitopes into host cells (e.g., yeast, mammalian, or insect cells), which then express and assemble the target protein. This approach ensures high purity, scalability, and consistency compared to traditional vaccine production methods.
SVTLE typically incorporates structural components critical for eliciting neutralizing antibodies, such as the spike (S) protein of viruses like SARS-CoV-2. Its design often includes stabilizing mutations (e.g., proline substitutions or disulfide bonds) to maintain prefusion conformation, enhancing immunogenicity. Adjuvants or fusion tags may be added to boost immune recognition or simplify purification.
The development of SVTLE-based vaccines addresses challenges like rapid pathogen mutation and immune evasion. By focusing on conserved regions or combining multiple antigenic domains, it aims to provide broad protection against variants. Preclinical and clinical studies have demonstrated its ability to induce robust humoral and cellular immune responses, with favorable safety profiles due to the absence of live viral components.
Such recombinant proteins are pivotal in modern vaccinology, offering adaptable platforms for emerging infectious diseases. Their thermostability and compatibility with existing manufacturing infrastructure further enhance global vaccine accessibility, making SVTLE a promising candidate for both preventive and therapeutic applications.
×
